Mr. White was named among Global Competition Review’s “40 Under 40” for 2015 and was recently recognized in Legal 500 as a “Next Generation Lawyer” for merger control. Mr. White also was previously honored with the Burton Award for Legal Achievement for co-authoring the article “Private Equity: Antitrust Concerns with Partial Acquisitions,” published in Antitrust, an American Bar Association publication.
Mr. White is an active member of the antitrust bar. For several years he served as Vice Chair of the American Bar Association Antitrust Section's Health Care and Pharmaceuticals Committee and the Executive Editor for the Committee's quarterly publication, the Antitrust Health Care Chronicle. He currently serves as Vice Chair of the Antitrust Section’s Distribution and Franchising Committee. He also has published a number of articles and other papers in the antitrust field, including generic drug merger enforcement, and actively participates in speaking engagements. He devotes time to pro bono work for the D.C. community, assisting the Washington Legal Clinic for the Homeless and aiding other local organizations.
Mr. White obtained his J.D. from the University of Virginia School of Law where he served as a member on both the Virginia Law Review and Virginia Tax Review.
Represented Allergan plc, a leading global pharmaceutical company, in the $39 billion sale of its global generic pharmaceuticals business to Teva Pharmaceutical Industries Ltd. (“Merger Control Matter of the Year” for the Americas, Global Competition Review Awards 2017).
Represented AbbVie, a global biopharmaceutical company, in its acquisition of Pharmacyclics, Inc., a transaction valued at $21 billion and which closed without the U.S. Federal Trade Commission issuing a Second Request, as well as its $5.8 billion acquisition of Stemcentrx.
Represented Providence Equity Partners in a private nationwide antitrust class action lawsuit asserting broad ranging antitrust conspiracy claims against Providence and other private equity firms in connection with multi-billion dollar leveraged buyouts dating back to 2003.
Represented Simon & Schuster in a high-profile series of private antitrust class actions and government investigations into the pricing of e-books, as well as a putative antitrust class action regarding digital rights management software.
Representing Straight Path Communications in its $3.1 billion sale to Verizon.
Represented Metaldyne Performance Group in its $3.3 billion sale to American Axle & Manufacturing.
Represented Arca Continental S.A.B. de C.V. in a multibillion-dollar bottling and distribution joint venture with Coca-Cola Co.
Represented OMERS/DTI in its $1 billion acquisition of Epiq Systems.
Represented Busch Vacuum in its proposed $1 billion takeover of Pfeiffer Vacuum.
Represented ALFA, S.A.B. de C.V., a major Mexican conglomerate, and its Alpek subsidiary, a leading provider of petrochemicals, in the acquisitions of the PET resins business of Wellman, Inc., and the PTA/PET resins business of Eastman Chemicals Company.
Represented a major global provider of medical devices, pharmaceuticals, and consumer goods in various high-profile acquisitions.